BIOCYTOGEN-B (02315) rose nearly 7% again. At the time of writing, the stock was up 5.08%, trading at HK$39.72, with a turnover of HK$28.32 million. On the news front, BIOCYTOGEN recently stated on an interactive platform that the company has completed the localized deployment of its AI-driven antibody drug research and development platform and has achieved full integration with its core initiative, the "Thousand Mice Ten Thousand Antibodies" project. Through the localized AI deployment, the company is currently developing an AI agent for antibody drug R&D. As the deep integration between the "Thousand Mice Ten Thousand Antibodies" project and the AI system continues to advance, the company will provide global pharmaceutical companies with more efficient R&D tools and a more extensive library of antibody molecules. This will help partner pharmaceutical companies improve the efficiency of preclinical PCC (Pharmacological and Chemical Characterization) molecule development, thereby propelling the antibody discovery business into a new phase of growth.